Ge Long Hui·2026-02-13 09:57Core Viewpoint - Fosun Pharma's subsidiary, GSK (Wuhan) Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of Cisplatin Injection by the National Medical Products Administration, indicating progress in the company's drug development pipeline [1] Group 1: Drug Development - The drug, Cisplatin Injection, is self-developed by the company and is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer [1] - As of January 2026, the company's cumulative R&D investment in this drug is approximately RMB 4.69 million (unaudited) [1] Group 2: Market Potential - According to the latest data from IQVIA CHPA, the sales revenue of Cisplatin Injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be approximately RMB 165 million in 2024 [1]